|        |                                                                     |
|--------|---------------------------------------------------------------------|
| x      | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE                |
|   | SECURITIES EXCHANGE ACT OF 1934                                     |
|   |                                                                |
|   | For the fiscal year ended December 31, 2010                         |
|   |                                                                |
|   | OR                                                                  |
|   |                                                                |
| o      | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE            |
|   | SECURITIES EXCHANGE ACT OF 1934                                     |
|   |                                                                |
|   | For the transition period from ________________ to ________________ |

|                                                                |        |                                      |
|----------------------------------------------------------------|--------|--------------------------------------|
| Nevada                                                         |   | 91-2015186                           |
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|                                                           |   |                                 |
| 2301 Crown Court, Irving, Texas                                |   | 75038                                |
| (Address of principal executive offices)                       |   | (Zip Code)                           |

|                                                             |                                |
|-------------------------------------------------------------|--------------------------------|
| Securities registered pursuant to Section 12(g) of the Act: | Common Stock, $0.001 par value |
|                                                        | (Title of class)               |

|                                                                     |                                               |                                              |
|---------------------------------------------------------------------|-----------------------------------------------|----------------------------------------------|
|        Large accelerated filer o |                                          | Accelerated filer o                          |
|        Non-accelerated filer o   | (Do not check if a smaller reporting company) | Smaller reporting company   R |

----

----

|            |                                                                                                                        |        |
|------------|------------------------------------------------------------------------------------------------------------------------|--------|
|       |                                                                                                                   | PAGE   |
|       |                                                                                                                   |   |
| PART I     |                                                                                                                   | 2      |
| Item 1.    | Business                                                                                                               | 14     |
| Item 1A.   | Risk Factors                                                                                                           | 21     |
| Item 1B.   | Unresolved Staff Comments                                                                                              | 21     |
| Item 2.    | Properties                                                                                                             | 21     |
| Item 3.    | Legal Proceedings                                                                                                      | 21     |
| Item 4.    | (Removed and Reserved)                                                                                                 | 21     |
|       |                                                                                                                   |   |
| PART II    |                                                                                                                   | 22     |
| Item 5.    | Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 22     |
| Item 6.    | Selected Financial Data                                                                                                | 22     |
| Item 7.    | Management’s Discussion and Analysis of Financial Condition and Results of Operations                            | 22     |
| Item 7A.   | Quantitative and Qualitative Disclosures About Market Risk                                                             | 30     |
| Item 8.    | Financial Statements and Supplementary Data                                                                            | 30     |
| Item 9.    | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                                   | 30     |
| Item 9A.   | Controls and Procedures                                                                                                | 31     |
| Item 9B.   | Other Information                                                                                                      | 31     |
|       |                                                                                                                   |   |
| PART III   |                                                                                                                   | 32     |
| Item 10.   | Directors, Executive Officers and Corporate Governance                                                                 | 32     |
| Item 11.   | Executive Compensation                                                                                                 | 32     |
| Item 12.   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                         | 32     |
| Item 13.   | Certain Relationships and Related Transactions, and Director Independence                                              | 32     |
| Item 14.   | Principal Accountant Fees and Services                                                                                 | 32     |
|       |                                                                                                                   |   |
| PART IV    |                                                                                                                   | 33     |
| Item 15.   | Exhibits and Financial Statement Schedules                                                                             | 33     |
|       |                                                                                                                   |   |
| SIGNATURES | 35                                                                                                                     |

----

|                                |                                                                                                                    |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------|
| •     | The aging population, particularly the baby-boomer generation, combined with the tendency on the part of consumers |

----

|                                |                                                                                                        |
|--------------------------------|--------------------------------------------------------------------------------------------------------|
| •     | The general public's heightened awareness and understanding of the connection between diet and health; |

|                                |                                                                                                                                                 |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Rising health care costs that lead many consumers to take preventive measures, including alternative medicines and nutritional supplements; and |

|                                |                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------|
| •     | The publication of research findings supporting the positive health effects of certain nutritional supplements. |

|                                |                                                                                                      |
|--------------------------------|------------------------------------------------------------------------------------------------------|
| •     | Mass market retailers, including mass merchandisers, drug stores, supermarkets, and discount stores; |

|                                |                                |
|--------------------------------|--------------------------------|
| •     | Natural health food retailers; |

|                                |                    |
|--------------------------------|--------------------|
| •     | Network marketing; |

|                                |             |
|--------------------------------|-------------|
| •     | Mail order; |

|                                |                                                  |
|--------------------------------|--------------------------------------------------|
| •     | Health care professionals and practitioners; and |

|                                |               |
|--------------------------------|---------------|
| •     | The Internet. |

|                                |                                                                |
|--------------------------------|----------------------------------------------------------------|
| •     | Wound management products such as adhesive bandages and gauze; |

|                                |                                                                    |
|--------------------------------|--------------------------------------------------------------------|
| •     | Wound closure products such as staples, various clips and sutures; |

|                                |                                                                                                                                                                                                              |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Advanced wound care products, which are represented by a variety of moist wound healing dressings such as alginate dressings, film dressings, foam dressings, hydrocolloid dressings and hydrogel dressings; |

|                                |                                                                                                 |
|--------------------------------|-------------------------------------------------------------------------------------------------|
| •     | Active wound healing products such as skin replacements, collagen dressings and growth factors; |

|                                |                                                     |
|--------------------------------|-----------------------------------------------------|
| •     | Debriding products including various cleansers; and |

|                                |                                                                                         |
|--------------------------------|-----------------------------------------------------------------------------------------|
| •     | Pressure relief devices such as beds, mattress overlays and other support devices. |

----

----

|                                |                                                                                 |
|--------------------------------|---------------------------------------------------------------------------------|
| •     | Microhydrin and Microhydrin Plus – powerful, broad-spectrum antioxidants; |

|                                |                                                                                                                                  |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| •     | NeuroBright® – introduced in August 2009, this product supports healthy brain function and enhances energy and acuity; |

|                                |                                                                                                                                                                                                                                                     |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Organic spirulina – sold in powder, tablet, capsule and, in combination with other ingredients, bar forms, a nutritious algae that provides a complete range of vital nutrients and a higher percentage of easily digested protein than meat; |

|                                |                                                                                                                                                                                  |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | OliViva® – made from freshly harvested olive leaves, an antioxidant beverage that supports the immune system, increases energy and supports the cardiovascular system; |

|                                |                                                                                                                                           |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| •     | ColoVada Plus® –  an effective fourteen-day colon cleansing program that has been widely used for more than 20 years; |

|                                |                                                                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | HydraCel® – a product that improves the quality of drinking water by reducing surface tension for increased hydration and making water more alkaline; |

|                                |                                                                |
|--------------------------------|----------------------------------------------------------------|
| •     | 24 Seven® – a daily multivitamin/mineral supplement; |

|                                |                                                                                             |
|--------------------------------|---------------------------------------------------------------------------------------------|
| •     | Immune 360® – a product to nourish and support the function of the immune system; |

|                                |                                                                                                                                         |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| •     | Digestion Formula – a combination of digestive enzymes to supplement the decline of enzymes that naturally occurs with aging; and |

|                                |                                                                                                                  |
|--------------------------------|------------------------------------------------------------------------------------------------------------------|
| •     | C7® – a science-based skin care product collection that incorporates ingredients with unique benefits. |

|                                |                                                                                                                                                                                                                   |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Silica mineral hydride, a nutritional antioxidant manufactured by us using our proprietary formula and process and used as an ingredient in the formulation of nutritional supplement and personal care products; |

|                                |                                                                                                                                                                                  |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Organic spirulina sourced from the highest quality producers, sold as a stand-alone product and combined as an ingredient in many other nutritional supplement formulations; and |

|                                |                                                                                                                                                                                                       |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Organic aloe vera specially processed to retain the benefits found in a fresh aloe vera leaf and sold as a beverage and as a topical gel and used as an ingredient in many of our skin care products. |

----

----

|                                |                                                                         |
|--------------------------------|-------------------------------------------------------------------------|
| •     | Through retail markups on sales of products purchased at wholesale; and |

|                                |                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------|
| •     | Through a series of commissions on product sales generated by the Associate and his or her downline Associates. |

----

----

----

----

----

----

----

|                                |                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------|
| •     | perception of our products, service level and business opportunity among our Associates and within our industry |

----

----

----

----

----

----

----

----

|                              |        |               |        |         |        |              |        |             |        |        |      |        |        |   |      |        |
|------------------------------|--------|---------------|--------|---------|--------|--------------|--------|-------------|--------|--------|------|--------|--------|---|------|--------|
|                         |   | Quarter Ended |
|                         |   | March 31      |   | June 30 |   | September 30 |   | December 31 |
| 2010                         |   |          |   |    |   |         |   |        |
|     HIGH |   | $             | 0.28   |    |   | $            | 0.38   |        |   | $      | 0.41 |   |   | $ | 0.37 |   |
|     LOW  |   | 0.20          |   |    | 0.22   |         |   | 0.25        |   |   | 0.25 |   |
|                         |   |          |   |    |   |         |   |        |
| 2009                         |   |          |   |    |   |         |   |        |
|     HIGH |   | $             | 0.50   |    |   | $            | 0.42   |        |   | $      | 0.41 |   |   | $ | 0.35 |   |
|     LOW  |   | 0.24          |   |    | 0.15   |         |   | 0.27        |   |   | 0.11 |   |

|                                                           |        |                                       |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |   |        |        |
|-----------------------------------------------------------|--------|---------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---|--------|--------|
|                                                      |   | Years Ended December 31,              |
|                                                      |   | 2010                                  |   | 2009   |   | 2008   |   | 2007   |   | 2006   |
|                                                      |   | (In thousands, except per share data) |
| Statement of Earnings Data:                               |   |                                  |   |   |   |   |   |   |   |   |
| Net sales                                                 |   | $                                     | 28,157 |   |   | $      | 24,925 |   |   | $      | 30,409 |   |   | $      | 27,029 |   |   | $ | 21,697 |   |
| Earnings (loss) before income taxes                       |   | 891                                   |   |   | (324   | )      |   | 2,677  |   |   | 2,689  |   |   | 714    |   |
| Net earnings (loss)                                       |   | 558                                   |   |   | (335   | )      |   | 1,616  |   |   | 1,692  |   |   | 436    |   |
| Net earnings (loss) per common share – diluted |   | 0.02                                  |   |   | (0.02  | )      |   | 0.07   |   |   | 0.08   |   |   | 0.02   |   |
| Balance Sheet Data:                                       |   |                                  |   |   |   |   |   |   |   |   |
| Cash and cash equivalents                                 |   | 4,220                                 |   |   | 3,972  |   |   | 4,973  |   |   | 6,369  |   |   | 3,220  |   |
| Working capital                                           |   | 5,513                                 |   |   | 4,676  |   |   | 5,275  |   |   | 3,539  |   |   | 1,935  |   |
| Total assets                                              |   | 18,344                                |   |   | 18,613 |   |   | 19,766 |   |   | 19,158 |   |   | 13,639 |   |
| Long-term obligations                                     |   | 1,896                                 |   |   | 2,052  |   |   | 2,196  |   |   | 2,332  |   |   | 2,924  |   |
| Shareholders' equity                                      |   | 9,876                                 |   |   | 9,219  |   |   | 9,387  |   |   | 7,578  |   |   | 5,607  |   |

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Through the Nutritional Products segment, we distribute products in three broad categories: (i) wellness products; (ii) fitness products; and (iii) skin care products.   Products include herbal formulas, vitamins, minerals, antioxidants and personal care products.  In certain markets, principally in the U.S. and Canada, we distribute Nutritional Products directly through a network of independent Associates. In certain international markets, we distribute Nutritional Products through exclusive license arrangements with third parties, who for the most part, distribute our products through an independent Associate network in the licensed territory. |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Through the Medical Products segment, we distribute wound care products.  These products are distributed primarily in the U.S. to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets. |

|                       |        |                          |        |        |        |                               |        |        |        |        |        |        |        |        |        |        |        |        |        |     |   |
|-----------------------|--------|--------------------------|--------|--------|--------|-------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-----|---|
|                  |   | Years Ended December 31, |
|                  |   | 2010                     |   | 2009   |   | 2008                          |
|                  |   |                     |   |   |   | (U.S. dollars in 000’s) |   |   |   |   |
| Nutritional Products: |   |                     |   |   |   |                          |   |   |   |   |   |   |
| Licensees             |   | $                        | 15,663 |   |   | 56                            | %      |   | $      | 12,839 |   |   | 51     | %      |   | $      | 18,375 |   |   | 60  | % |
| Associate network     |   | 5,950                    |   |   | 21     | %                             |   | 5,940  |   |   | 24     | %      |   | 5,686  |   |   | 19     | %      |
|                  |   | 21,613                   |   |   | 77     | %                             |   | 18,779 |   |   | 75     | %      |   | 24,061 |   |   | 79     | %      |
| Medical Products      |   | 6,544                    |   |   | 23     | %                             |   | 6,146  |   |   | 25     | %      |   | 6,348  |   |   | 21     | %      |
|                  |   | $                        | 28,157 |   |   | 100                           | %      |   | $      | 24,925 |   |   | 100    | %      |   | $      | 30,409 |   |   | 100 | % |

----

|                |        |                                         |        |        |         |      |        |         |   |
|----------------|--------|-----------------------------------------|--------|--------|---------|------|--------|---------|---|
|           |   | Years Ended December 31, |
|           |   | 2010                                    |   | 2009   |    | 2008 |
| U.S.           |   | 72                                      | %      |   | 82      | %    |   | 80      | % |
| Canada         |   | 18                                      | %      |   | 18      | %    |   | 20      | % |
| Southeast Asia |   | 10                                      | %      |   | — | %    |   | — | % |
|           |   | 100                                     | %      |   | 100     | %    |   | 100     | % |

----

----

|                                                                                                             |        |                                         |        |        |         |         |        |        |   |
|-------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------|--------|--------|---------|---------|--------|--------|---|
|                                                                                                        |   | Years Ended December 31, |
|                                                                                                        |   | 2010                                    |   | 2009   |    | 2008    |
| Net sales                                                                                                   |   | 100.0                                   | %      |   | 100.0   |  % |   | 100.0  | % |
| Cost of sales                                                                                               |   | 51.4                                    | %      |   | 48.6    |  % |   | 49.0   | % |
|             Gross profit                        |   | 48.6                                    | %      |   | 51.4    |  % |   | 51.0   | % |
| Operating expenses:                                                                                         |   |                                    |   |   |    |    |   |   |
|       General and administrative                                              |   | 32.8                                    | %      |   | 40.4    |  % |   | 32.9   | % |
|       Distributor commissions                                                 |   | 10.4                                    | %      |   | 10.0    |  % |   | 7.6    | % |
|       Depreciation and amortization                                           |   | 1.7                                     | %      |   | 1.6     |  % |   | 1.1    | % |
|             Total operating expenses            |   | 44.9                                    | %      |   | 52.0    |  % |   | 41.6   | % |
|             Operating profit (loss)             |   | 3.7                                     | %      |   | (0.6    | )%      |   | 9.4    | % |
| Interest expense                                                                                            |   | 0.5                                     | %      |   | 0.7     |  % |   | 0.6    | % |
|             Earnings (loss) before income taxes |   | 3.2                                     | %      |   | (1.3    | )%      |   | 8.8    | % |
| Income tax expense                                                                                          |   | 1.2                                     | %      |   | — |  % |   | 3.5    | % |
|             Net earnings (loss)                 |   | 2.0                                     | %      |   | (1.3    | )%      |   | 5.3    | % |

----

----

|                                |                                                                                                                            |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| •     | The level of recruiting and retention of Associates in North America, NFR markets and territories served by our licensees; |

|                                |                                                                              |
|--------------------------------|------------------------------------------------------------------------------|
| •     | Variations in the level of business activity generated by our key customers; |

----

|                                |                             |
|--------------------------------|-----------------------------|
| •     | The opening of new markets; |

|                                |                                                                                                            |
|--------------------------------|------------------------------------------------------------------------------------------------------------|
| •     | The timing and efficacy of Company-sponsored events, promotions and other marketing and sales initiatives; |

|                                |                            |
|--------------------------------|----------------------------|
| •     | New product introductions; |

|                                |                                                                                                                                                                        |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | The negative impact of new regulations or changes in existing regulations domestically and/or internationally that may limit or restrict the sale of certain products; |

|                                |                                                                      |
|--------------------------------|----------------------------------------------------------------------|
| •     | The integration and operation of new information technology systems; |

|                                |                                                                                             |
|--------------------------------|---------------------------------------------------------------------------------------------|
| •     | The inability to introduce new products or the introduction of new products by competitors; |

|                                |                                                           |
|--------------------------------|-----------------------------------------------------------|
| •     | Entry into one or more of our markets by competitors; and |

|                                |                                                                                                                        |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------|
| •     | General conditions in the nutritional supplement industry, the network marketing industry and the wound care industry. |

----

|                          |        |                                      |        |        |       |        |        |           |        |        |           |        |        |                 |        |        |   |     |        |
|--------------------------|--------|--------------------------------------|--------|--------|-------|--------|--------|-----------|--------|--------|-----------|--------|--------|-----------------|--------|--------|---|-----|--------|
|                     |   | Payments Due by Period (000’s) |
| Contractual Obligations  |   | Total                                |   |   | 2011  |   |   | 2012-2013 |   |   | 2014-2015 |   |   | 2016 and beyond |   |
| Long-term debt           |   | 1,896                                |   |   | $     | 169    |   |      | $      | 378    |      |   | $      | 442             |   |   | $ | 907 |   |
| Operating leases         |   | 180                                  |   |   | 98    |   |   | 82        |   |   | —   |   |   | —         |   |
| Purchase obligations (1) |   | 3,435                                |   |   | 3,435 |   |   | —   |   |   | —   |   |   | —         |   |
| Employment agreements    |   | 2,503                                |   |   | 1,415 |   |   | 742       |   |   | 346       |   |   | —         |   |

----

----

----

|         |        |                                                                                                                                                                                                                                                     |
|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ex. No. |   | Description                                                                                                                                                                                                                                         |
|    |   |                                                                                                                                                                                                                                                |
| 3.1     |   | Articles of Incorporation (2)                                                                                                                                                                                                                       |
|    |   |                                                                                                                                                                                                                                                |
| 3.2     |   | Bylaws (2)                                                                                                                                                                                                                                          |
|    |   |                                                                                                                                                                                                                                                |
| 3.3     |   | Amendment No. 1 to Bylaws (6)                                                                                                                                                                                                                       |
|    |   |                                                                                                                                                                                                                                                |
| 3.3     |   | Amendment No. 2 to Bylaws (12)                                                                                                                                                                                                                      |
|    |   |                                                                                                                                                                                                                                                |
| 4.1     |   | Specimen copy of Certificate for Common Stock (2)                                                                                                                                                                                                   |
|    |   |                                                                                                                                                                                                                                                |
| 4.2     |   | The 2003 Stock Incentive Plan (4)                                                                                                                                                                                                                   |
|    |   |                                                                                                                                                                                                                                                |
| 4.3     |   | The 2006 Stock Incentive Plan (9)                                                                                                                                                                                                                   |
|    |   |                                                                                                                                                                                                                                                |
| 10.1    |   | Form of Member Agreement and Policies with Distributors (1)                                                                                                                                                                                         |
|    |   |                                                                                                                                                                                                                                                |
| 10.2    |   | Form of Indemnification Agreement (2)                                                                                                                                                                                                               |
|    |   |                                                                                                                                                                                                                                                |
| 10.3    |   | Purchase and Sale Agreement, dated as of August 21, 2000, between CIIF Associates II Limited Partnership and Royal BodyCare, Inc.(3)                                                                                                                |
|    |   |                                                                                                                                                                                                                                                |
| 10.4    |   | Mortgage Note, dated March 15, 2001, in the principal amount of $3,000,000, executed by Royal BodyCare, Inc. and Clinton H. Howard in favor of Allstate Life Insurance Company(10)                                                                  |
|    |   |                                                                                                                                                                                                                                                |
| 10.5    |   | Deed of Trust, Assignment of Leases, Rents and Contracts, Security Agreement and Fixture Filing, dated March 16, 2001, between Royal BodyCare, Inc., as Trustor, Robin R. Green, as Trustee and Allstate Life Insurance Company, as Beneficiary(10) |
|    |   |                                                                                                                                                                                                                                                |
| 10.6    |   | Exclusive Distributorship Agreement, dated as of July 14, 2004, between Royal BodyCare, Inc. and Coral Club International, Inc.(8)                                                                                                                  |
|    |   |                                                                                                                                                                                                                                                |
| 10.7    |   | Employment Agreement, executed December 11, 2009 to be effective January 1, 2010, between RBC Life Sciences, Inc. and Steven E. Brown (11)                                                                                                          |
|    |   |                                                                                                                                                                                                                                                |
| 10.8    |   | Employment Agreement, executed December 22, 2009 to be effective January 1, 2010, between RBC Life Sciences, Inc. and Kenneth L. Sabot (11)                                                                                                         |

----

|        |        |                                                                                                                                                        |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                   |
| 10.9   |   | Severance and Consulting Agreement and General Release executed June 16, 2010 between John W. Price and RBC Life Sciences USA, Inc. (13)               |
|   |   |                                                                                                                                                   |
| 10.10  |   | Employment Agreement dated August 3, 2010 between RBC Life Sciences, Inc. and Clinton H. Howard (14)                                                   |
|   |   |                                                                                                                                                   |
| 14.1   |   | Code of Ethics(7)                                                                                                                                      |
|   |   |                                                                                                                                                   |
| 21.1   |   | List of company subsidiaries*                                                                                                                          |
|   |   |                                                                                                                                                   |
| 23.1   |   | Consent of Lane Gorman Trubitt, PLLC, independent registered public accountants to incorporation of report by reference *                         |
|   |   |                                                                                                                                                   |
| 23.2   |   | Consent of  Gardere Wynne Sewell LLP, legal counsel (5)                                                                                      |
|   |   |                                                                                                                                                   |
| 24.1   |   | Power of Attorney (5)                                                                                                                                  |
|   |   |                                                                                                                                                   |
| 31.1   |   | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*                                                |
|   |   |                                                                                                                                                   |
| 31.2   |   | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*                                                |
|   |   |                                                                                                                                                   |
| 32.1   |   | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |
|   |   |                                                                                                                                                   |
| 32.2   |   | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |

----

|        |                     |                          |                                            |
|--------|---------------------|--------------------------|--------------------------------------------|
|   |                | RBC LIFE SCIENCES, INC., |
|   |                | a Nevada corporation     |
|   |                |                     |                                       |
| Date:  | March 15, 2011 | By:                      | /s/ Clinton H. Howard                      |
|   |                |                     | Clinton H. Howard, Chief Executive Officer |

|                        |        |                                       |        |                     |
|------------------------|--------|---------------------------------------|--------|---------------------|
| Signature              |   | Title                                 |   | Date                |
|                   |   |                                  |   |                |
| /s/ Clinton H. Howard  |   | Chairman of the Board of Directors,   |   |                |
| Clinton H. Howard      |   | President and Chief Executive Officer |   |                |
|                   |   | (principal executive officer)         |   | March 15, 2011 |
|                   |   |                                  |   |                |
| /s/ Steven E. Brown    |   | Director, Vice President-Finance and  |   |                |
| Steven E. Brown        |   | Chief Financial Officer               |   |                |
|                   |   | (principal financial and accounting   |   |                |
|                   |   | officer)                              |   | March 15, 2011 |
|                   |   |                                  |   |                |
| /s/ Paul R. Miller     |   | Director and President-               |   | March 15, 2011 |
| Paul R. Miller         |   | MPM Medical, Inc.                     |   |                |
|                   |   |                                  |   |                |
| /s/ Joseph. P. Philipp |   | Director                              |   |                |
| Joseph P. Philipp      |   |                                  |   | March 15, 2011 |
|                   |   |                                  |   |                |
| /s/ Robert A. Kaiser   |   | Director                              |   |                |
| Robert A. Kaiser       |   |                                  |   | March 15, 2011 |
|                   |   |                                  |   |                |
| /s/ Kenneth L. Sabot   |   | Director                              |   | March 15, 2011 |
| Kenneth L. Sabot       |   |                                  |   |                |
|                   |   |                                  |   |                |
| /s/ Andrew V. Howard   |   | Director                              |   | March 15, 2011 |
| Andrew V. Howard       |   |                                  |   |                |

----

|                                                         |        |
|---------------------------------------------------------|--------|
|                                                    | Page   |
|                                                    |   |
| Report of Independent Registered Public Accounting Firm | F-2    |
|                                                    |   |
| Consolidated Financial Statements                       |   |
|                                                    |   |
| Consolidated Balance Sheets                             | F-3    |
|                                                    |   |
| Consolidated Statements of Operations                   | F-4    |
|                                                    |   |
| Consolidated Statements of Shareholders’ Equity   | F-5    |
|                                                    |   |
| Consolidated Statements of Cash Flows                   | F-6    |
|                                                    |   |
| Notes to Consolidated Financial Statements              | F-7    |

----

----

|                                                                                                                                                                        |        |            |            |        |            |        |            |        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|------------|--------|------------|--------|------------|--------|
|                                                                                                                                                                   |   | 2010       |       | 2009   |
| ASSETS                                                                                                                                                                 |   |       |       |   |
| Current assets                                                                                                                                                         |   |       |       |   |
| Cash and cash equivalents                                                                                                                                              |   | $          | 4,220,152  |   |       | $      | 3,972,111  |   |
| Accounts receivable, net of allowance for doubtful accounts of $30,357 and $28,030, respectively                                                                       |   | 491,576    |       |   | 576,125    |   |
| Inventories                                                                                                                                                            |   | 5,343,016  |       |   | 5,344,259  |   |
| Deferred income taxes                                                                                                                                                  |   | 396,415    |       |   | 449,254    |   |
| Prepaid expenses and other current assets                                                                                                                              |   | 807,344    |       |   | 888,303    |   |
| Total current assets                                                                                                                                                   |   | 11,258,503 |       |   | 11,230,052 |   |
| Property and equipment, net of accumulated depreciation                                                                                                                |   | 4,638,075  |       |   | 5,037,890  |   |
| Goodwill, net of accumulated amortization                                                                                                                              |   | 2,295,270  |       |   | 2,271,977  |   |
| Other intangible assets, net of accumulated amortization                                                                                                               |   | 55,851     |       |   | 61,808     |   |
| Other assets                                                                                                                                                           |   | 95,813     |       |   | 10,897     |   |
|                                                                                                                                                                   |   | $          | 18,343,512 |   |       | $      | 18,612,624 |   |
| LIABILITIES AND SHAREHOLDERS' EQUITY                                                                                                                                   |   |       |       |   |       |   |
| Current liabilities                                                                                                                                                    |   |       |       |   |       |   |
| Accounts payable, trade                                                                                                                                                |   | $          | 2,110,624  |   |       | $      | 1,803,997  |   |
| Accrued liabilities                                                                                                                                                    |   | 976,495    |       |   | 925,060    |   |
| Current maturities of long-term obligations                                                                                                                            |   | 168,522    |       |   | 155,994    |   |
| Deferred revenue                                                                                                                                                       |   | 2,489,828  |       |   | 3,668,907  |   |
| Total current liabilities                                                                                                                                              |   | 5,745,469  |       |   | 6,553,958  |   |
| Long-term obligations, less current maturities                                                                                                                         |   | 1,727,555  |       |   | 1,896,077  |   |
| Deferred income taxes                                                                                                                                                  |   | 994,909    |       |   | 943,235    |   |
| Commitments and contingencies                                                                                                                                          |   |       |       |   |       |   |
| Shareholders' equity                                                                                                                                                   |   |       |       |   |       |   |
| Preferred stock, $0.10 par value; authorized 20,000,000 shares; none outstanding                                                                                       |   | —    |       |   | —    |   |
| Common stock, $0.001 par value; authorized 50,000,000 shares; 22,228,834 and 21,921,934                   shares issued and outstanding in 2010 and 2009, respectively |   | 22,229     |       |   | 21,922     |   |
| Additional paid-in capital                                                                                                                                             |   | 13,605,922 |       |   | 13,504,874 |   |
| Accumulated deficit                                                                                                                                                    |   | (3,881,348 | )          |   | (4,439,094 | )      |
| Accumulated other comprehensive income                                                                                                                                 |   | 128,776    |       |   | 131,652    |   |
|                                                                                                                                                                   |   | 9,875,579  |       |   | 9,219,354  |   |
|                                                                                                                                                                   |   | $          | 18,343,512 |   |       | $      | 18,612,624 |   |

----

|                                             |        |            |            |        |            |        |            |            |        |   |            |        |
|---------------------------------------------|--------|------------|------------|--------|------------|--------|------------|------------|--------|---|------------|--------|
|                                        |   | 2010       |       | 2009   |       | 2008   |
| Net sales                                   |   | $          | 28,157,010 |   |       | $      | 24,924,581 |       |   | $ | 30,409,293 |   |
| Cost of sales                               |   | 14,471,200 |       |   | 12,122,702 |   |       | 14,914,840 |   |
| Gross profit                                |   | 13,685,810 |       |   | 12,801,879 |   |       | 15,494,453 |   |
| Operating expenses                          |   |       |       |   |       |   |       |       |   |
| General and administrative                  |   | 9,228,190  |       |   | 10,061,487 |   |       | 10,012,438 |   |
| Distributor commissions                     |   | 2,937,851  |       |   | 2,497,651  |   |       | 2,293,841  |   |
| Depreciation and amortization               |   | 475,998    |       |   | 402,358    |   |       | 336,522    |   |
| Total operating expenses                    |   | 12,642,039 |       |   | 12,961,496 |   |       | 12,642,801 |   |
| Operating profit (loss)                     |   | 1,043,771  |       |   | (159,617   | )      |       | 2,851,652  |   |
| Interest expense                            |   | 152,564    |       |   | 164,236    |   |       | 175,055    |   |
| Earnings (loss) before income taxes         |   | 891,207    |       |   | (323,853   | )      |       | 2,676,597  |   |
| Income tax expense                          |   | 333,461    |       |   | 11,000     |   |       | 1,060,837  |   |
| Net earnings (loss)                         |   | $          | 557,746    |   |       | $      | (334,853   | )          |   | $ | 1,615,760  |   |
| Basic earnings (loss) per share             |   | $          | 0.03       |   |       | $      | (0.02      | )          |   | $ | 0.08       |   |
| Basic weighted average shares outstanding   |   | 21,998,659 |       |   | 21,920,779 |   |       | 21,464,832 |   |
| Diluted earnings (loss) per share           |   | $          | 0.02       |   |       | $      | (0.02      | )          |   | $ | 0.07       |   |
| Diluted weighted average shares outstanding |   | 22,435,697 |       |   | 21,920,779 |   |       | 22,838,858 |   |

----

|                                         |        |              |        |         |         |             |        |               |        |                     |            |        |        |            |        |        |           |         |        |        |   |           |        |
|-----------------------------------------|--------|--------------|--------|---------|---------|-------------|--------|---------------|--------|---------------------|------------|--------|--------|------------|--------|--------|-----------|---------|--------|--------|---|-----------|--------|
|                                    |   |         |   |    |    | Additional  |   |          |   | Accumulated other   |       | Total  |
|                                    |   | Common stock |   | paid-in |    | Accumulated |   | comprehensive |   | shareholders’ |
|                                    |   | Shares       |   | Amount  |    | capital     |   | deficit       |   | income              |       | equity |
| Balance at January 1, 2008              |   | 20,863,724   |   |    | $       | 20,864      |   |          | $      | 13,086,182          |       |   | $      | (5,720,001 | )      |   | $         | 191,080 |   |   | $ | 7,578,125 |   |
| Comprehensive income (loss)             |   |         |   |    |    |        |   |          |   |                |       |   |   |       |   |   |      |    |
| Net earnings                            |   | —      |   |    | — |        |   | —       |   |                | 1,615,760  |   |   | —    |   |   | 1,615,760 |    |
| Foreign currency translation adjustment |   | —      |   |    | — |        |   | —       |   |                | —    |   |   | (86,158    | )      |   | (86,158   | )       |
| Total comprehensive income              |   |    |   |    |    |        |   |          |   |                |       |   |   |       |   |   | 1,529,602 |    |
| Exercise of common stock options        |   | 1,051,280    |   |    | 1,051   |        |   | 156,549       |   |                | —    |   |   | —    |   |   | 157,600   |    |
| Share-based compensation                |   | —      |   |    | — |        |   | 121,577       |   |                | —    |   |   | —    |   |   | 121,577   |    |
| Balance at December 31, 2008            |   | 21,915,004   |   |    | 21,915  |        |   | 13,364,308    |   |                | (4,104,241 | )      |   | 104,922    |   |   | 9,386,904 |    |
| Comprehensive income (loss)             |   |         |   |    |    |        |   |          |   |                |       |   |   |       |   |   |      |    |
| Net loss                                |   | —      |   |    | — |        |   | —       |   |                | (334,853   | )      |   | —    |   |   | (334,853  | )       |
| Foreign currency translation adjustment |   | —      |   |    | — |        |   | —       |   |                | —    |   |   | 26,730     |   |   | 26,730    |    |
| Total comprehensive loss                |   |    |   |    |    |        |   |          |   |                |       |   |   |       |   |   | (308,123  | )       |
| Exercise of common stock options        |   | 6,930        |   |    | 7       |        |   | 1,448         |   |                | —    |   |   | —    |   |   | 1,455     |    |
| Share-based compensation                |   | —      |   |    | — |        |   | 139,118       |   |                | —    |   |   | —    |   |   | 139,118   |    |
| Balance at December 31, 2009            |   | 21,921,934   |   |    | 21,922  |        |   | 13,504,874    |   |                | (4,439,094 | )      |   | 131,652    |   |   | 9,219,354 |    |
| Comprehensive income (loss)             |   |         |   |    |    |        |   |          |   |                |       |   |   |       |   |   |      |    |
| Net earnings                            |   | —      |   |    | — |        |   | —       |   |                | 557,746    |   |   | —    |   |   | 557,746   |    |
| Foreign currency translation adjustment |   | —      |   |    | — |        |   | —       |   |                | —    |   |   | (2,876     | )      |   | (2,876    | )       |
| Total comprehensive income              |   |         |   |    |    |        |   |          |   |                |       |   |   |       |   |   | 554,870   |    |
| Exercise of common stock options        |   | 306,900      |   |    | 307     |        |   | 44,612        |   |                | —    |   |   | —    |   |   | 44,919    |    |
| Share-based compensation                |   | —      |   |    | — |        |   | 56,436        |   |                | —    |   |   | —    |   |   | 56,436    |    |
| Balance at December 31, 2010            |   | 22,228,834   |   |    | $       | 22,229      |   |          | $      | 13,605,922          |       |   | $      | (3,881,348 | )      |   | $         | 128,776 |   |   | $ | 9,875,579 |   |

----

|                                                                                                     |        |            |           |        |            |        |           |            |        |   |           |        |
|-----------------------------------------------------------------------------------------------------|--------|------------|-----------|--------|------------|--------|-----------|------------|--------|---|-----------|--------|
|                                                                                                |   | 2010       |      | 2009   |       | 2008   |
| Cash flows from operating activities                                                                |   |       |      |   |       |   |
| Net earnings (loss)                                                                                 |   | $          | 557,746   |   |       | $      | (334,853  | )          |   | $ | 1,615,760 |   |
| Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities |   |       |      |   |       |   |      |
| Depreciation and amortization                                                                       |   | 539,289    |      |   | 455,603    |   |      | 373,811    |   |
| Loss on disposition of assets                                                                       |   | 23,071     |      |   | 23,504     |   |      | —    |   |
| Deferred income taxes                                                                               |   | 104,513    |      |   | 222,772    |   |      | 117,339    |   |
| Share-based compensation                                                                            |   | 56,436     |      |   | 139,118    |   |      | 121,577    |   |
| Change in operating assets and liabilities                                                          |   |       |      |   |       |   |      |       |
| Accounts receivable                                                                                 |   | 84,914     |      |   | (111,076   | )      |      | 222,194    |   |
| Inventories                                                                                         |   | 6,310      |      |   | 386,558    |   |      | (1,011,530 | )      |
| Prepaid expenses and other current assets                                                           |   | 84,785     |      |   | 499,473    |   |      | (1,081,026 | )      |
| Other assets                                                                                        |   | (84,722    | )         |   | —    |   |      | (7,417     | )      |
| Accounts payable, trade                                                                             |   | 303,759    |      |   | (161,422   | )      |      | 37,475     |   |
| Accrued liabilities                                                                                 |   | 49,773     |      |   | (351,129   | )      |      | (1,215,469 | )      |
| Deferred revenue                                                                                    |   | (1,181,143 | )         |   | (610,228   | )      |      | (44,813    | )      |
| Net cash provided by (used in) operating activities                                                 |   | 544,731    |      |   | 158,320    |   |      | (872,099   | )      |
| Cash flows from investing activities                                                                |   |       |      |   |       |   |      |       |   |
| Purchase of property and equipment                                                                  |   | (163,269   | )         |   | (1,134,752 | )      |      | (590,907   | )      |
| Proceeds from insurance policy                                                                      |   | —    |      |   | 194,278    |   |      | —    |   |
| Proceeds from sale of equipment                                                                     |   | 6,979      |      |   | —    |   |      | —    |   |
| Net cash used in investing activities                                                               |   | (156,290   | )         |   | (940,474   | )      |      | (590,907   | )      |
| Cash flows from financing activities                                                                |   |       |      |   |       |   |      |       |   |
| Exercise of common stock options                                                                    |   | 44,919     |      |   | 1,455      |   |      | 157,600    |   |
| Payments of long-term debt                                                                          |   | (155,994   | )         |   | (144,397   | )      |      | (135,428   | )      |
| Net cash provided by (used in) financing activities                                                 |   | (111,075   | )         |   | (142,942   | )      |      | 22,172     |   |
| Effect of exchange rate changes on cash flows                                                       |   | (29,325    | )         |   | (76,198    | )      |      | 45,354     |   |
| Net increase (decrease) in cash                                                                     |   | 248,041    |      |   | (1,001,294 | )      |      | (1,395,480 | )      |
| Cash and cash equivalents at beginning of year                                                      |   | 3,972,111  |      |   | 4,973,405  |   |      | 6,368,885  |   |
| Cash and cash equivalents at end of year                                                            |   | $          | 4,220,152 |   |       | $      | 3,972,111 |       |   | $ | 4,973,405 |   |
| Supplemental cash flow disclosures                                                                  |   |       |      |   |       |   |      |       |   |
| Interest paid                                                                                       |   | $          | 153,572   |   |       | $      | 165,169   |       |   | $ | 175,934   |   |
| Income taxes paid                                                                              |   | 23,613     |      |   | 69,621     |   |      | 2,181,912  |   |

----

----

----

----

|                                             |        |         |         |        |         |        |         |        |
|---------------------------------------------|--------|---------|---------|--------|---------|--------|---------|--------|
|                                        |   | 2010    |    | 2009   |
| Accounts receivable                         |   |    |    |   |
| Trade                                       |   | $       | 521,330 |   |    | $      | 600,363 |   |
| Other                                  |   | 603     |    |   | 3,792   |   |
| Total                                       |   | 521,933 |    |   | 604,155 |   |
| Less allowance for doubtful accounts   |   | 30,357  |    |   | 28,030  |   |
| Net accounts receivable                     |   | $       | 491,576 |   |    | $      | 576,125 |   |

|                      |        |        |        |        |         |        |        |        |
|----------------------|--------|--------|--------|--------|---------|--------|--------|--------|
|                 |   | 2010   |   | 2009   |
| Beginning balance    |   | $      | 28,030 |   |    | $      | 36,573 |   |
| Bad debt provision   |   | 7,234  |   |   | 4,066   |   |
| Accounts written off |   | (4,907 | )      |   | (12,609 | )      |
| Ending balance       |   | $      | 30,357 |   |    | $      | 28,030 |   |

|                                 |        |           |           |        |           |        |           |        |
|---------------------------------|--------|-----------|-----------|--------|-----------|--------|-----------|--------|
|                            |   | 2010      |      | 2009   |
| Raw materials and bulk products |   | $         | 287,644   |   |      | $      | 403,616   |   |
| Packaging materials             |   | 318,397   |      |   | 488,545   |   |
| Finished goods                  |   | 4,736,975 |      |   | 4,452,098 |   |
|                            |   | $         | 5,343,016 |   |      | $      | 5,344,259 |   |

|                                            |        |         |         |        |         |        |         |        |
|--------------------------------------------|--------|---------|---------|--------|---------|--------|---------|--------|
|                                       |   | 2010    |    | 2009   |
| Advance payments to suppliers              |   | $       | 333,763 |   |    | $      | 177,415 |   |
| Prepaid income taxes                       |   | 225,698 |    |   | 453,177 |   |
| Certificates of deposit – restricted |   | 84,923  |    |   | 81,252  |   |
| Prepaid insurance and other                |   | 162,960 |    |   | 176,459 |   |
| Total                                      |   | $       | 807,344 |   |    | $      | 888,303 |   |

----

|                                                |        |           |           |        |           |        |           |        |
|------------------------------------------------|--------|-----------|-----------|--------|-----------|--------|-----------|--------|
|                                           |   | 2010      |      | 2009   |
| Building and improvements                      |   | $         | 3,523,428 |   |      | $      | 3,523,428 |   |
| Computer software and office equipment         |   | 2,063,488 |      |   | 2,314,849 |   |
| Warehouse equipment                            |   | 219,030   |      |   | 286,731   |   |
| Automotive equipment                           |   | 15,228    |      |   | 15,228    |   |
| Leasehold improvements                         |   | —   |      |   | 20,894    |   |
|                                           |   | 5,821,174 |      |   | 6,161,130 |   |
| Less accumulated depreciation and amortization |   | 2,324,272 |      |   | 2,264,413 |   |
|                                           |   | 3,496,902 |      |   | 3,896,717 |   |
| Land                                           |   | 1,141,173 |      |   | 1,141,173 |   |
|                                           |   | $         | 4,638,075 |   |      | $      | 5,037,890 |   |

|                                 |        |                    |           |                         |            |   |            |   |
|---------------------------------|--------|--------------------|-----------|-------------------------|------------|---|------------|---|
|                            |   | GrossCarryingValue |      | AccumulatedAmortization |
| Balance, January 1, 2009        |   | $                  | 3,238,342 |                    |       | $ | (1,041,260 | ) |
| Currency translation adjustment |   | 146,145            |      |                    | (71,250    | ) |
| Balance, December 31, 2009      |   | 3,384,487          |      |                    | (1,112,510 | ) |
| Currency translation adjustment |   | 45,453             |      |                    | (22,160    | ) |
| Balance, December 31, 2010      |   | $                  | 3,429,940 |                    |       | $ | (1,134,670 | ) |

|                                                |        |                    |        |                    |         |                         |         |                    |         |                    |        |                         |        |        |         |        |        |   |         |   |
|------------------------------------------------|--------|--------------------|--------|--------------------|---------|-------------------------|---------|--------------------|---------|--------------------|--------|-------------------------|--------|--------|---------|--------|--------|---|---------|---|
|                                           |   | 2010               |   | 2009               |
|                                           |   | AverageLife(years) |   | GrossCarryingValue |    | AccumulatedAmortization |    | AverageLife(years) |    | GrossCarryingValue |   | AccumulatedAmortization |
| Copyrights, trademarks and other registrations |   | 19                 |   | 99,100             |    |                    | (49,549 | )                  |    | 19                 |   | 99,100                  |   |   | (44,264 | )      |
| Other                                          |   | 19                 |   | 12,600             |    |                    | (6,300  | )                  |    | 19                 |   | 12,600                  |   |   | (5,628  | )      |
|                                           |   |               |   | $                  | 111,700 |                    |    | $                  | (55,849 | )                  |   |                    |   | $      | 111,700 |   |   | $ | (49,892 | ) |

----

|                         |        |        |        |
|-------------------------|--------|--------|--------|
| Year ended December 31, |   |
| 2011                    | $      | 5,957  |   |
| 2012                    | 5,957  |   |
| 2013                    | 5,957  |   |
| 2014                    | 5,957  |   |
| 2015                    | 5,957  |   |
| Thereafter              | 26,066 |   |
|                    | $      | 55,851 |   |

|                          |        |         |         |        |         |        |         |        |
|--------------------------|--------|---------|---------|--------|---------|--------|---------|--------|
|                     |   | 2010    |    | 2009   |
| Distributor commissions  |   | $       | 470,778 |   |    | $      | 317,562 |   |
| Salaries and wages       |   | 399,357 |    |   | 436,916 |   |
| Sales and property taxes |   | 31,422  |    |   | 40,684  |   |
| Interest                 |   | 12,246  |    |   | 13,253  |   |
| Other                    |   | 62,692  |    |   | 116,645 |   |
| Total                    |   | $       | 976,495 |   |    | $      | 925,060 |   |

|                                                                                                                                                                                                                                                  |        |         |           |        |         |        |           |        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|-----------|--------|---------|--------|-----------|--------|
|                                                                                                                                                                                                                                             |   | 2010    |      | 2009   |
| Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s CEO and Chairman of the Board of Directors |   | $       | 1,896,077 |   |    | $      | 2,052,071 |   |
| Less – current maturities                                                                                                                                                                                                                  |   | 168,522 |      |   | 155,994 |   |
|                                                                                                                                                                                                                                             |   | $       | 1,727,555 |   |    | $      | 1,896,077 |   |

|                         |         |           |        |
|-------------------------|---------|-----------|--------|
| Year ended December 31, |    |
| 2011                    | $       | 168,522   |   |
| 2012                    | 182,056 |      |
| 2013                    | 196,678 |      |
| 2014                    | 212,474 |      |
| 2015                    | 229,538 |      |
| Thereafter              | 906,809 |      |
|                    | $       | 1,896,077 |   |

----

|                                        |        |                         |        |        |         |        |        |         |        |
|----------------------------------------|--------|-------------------------|--------|--------|---------|--------|--------|---------|--------|
|                                   |   | Year Ended December 31, |
|                                   |   | 2010                    |   | 2009   |    | 2008   |
| Weighted average expected life (years) |   | 9.0                     |   |   | 7.2     |   |   | 8.6     |   |
| Risk-free interest rate                |   | 3.09                    | %      |   | 2.70    | %      |   | 2.95    | %      |
| Expected volatility                    |   | 105.02                  | %      |   | 113.05  | %      |   | 128.07  | %      |
| Expected dividend yield                |   | —                 | %      |   | — | %      |   | — | %      |

----

|                                  |        |            |        |                                               |        |                                                          |        |                         |        |        |        |   |        |        |
|----------------------------------|--------|------------|--------|-----------------------------------------------|--------|----------------------------------------------------------|--------|-------------------------|--------|--------|--------|---|--------|--------|
|                             |   | Options    |   | Weighted-Average ExercisePrice per Share |   | Weighted-AverageRemainingContractual Term(in years) |   | AggregateIntrinsicValue |
| Outstanding on January 1, 2008   |   | 3,494,950  |   |                                          | $      | 0.32                                                     |   |                    |   |   |   |
| Granted                          |   | 420,650    |   |                                          | 0.58   |                                                     |   |                    |   |   |
| Exercised                        |   | (1,051,280 | )      |                                          | 0.15   |                                                     |   |                    |   |   |
| Forfeited/Canceled               |   | (571,435   | )      |                                          | 0.23   |                                                     |   |                    |   |   |
| Outstanding on December 31, 2008 |   | 2,292,885  |   |                                          | 0.46   |                                                     |   |                    |   |   |
| Granted                          |   | 401,885    |   |                                          | 0.44   |                                                     |   |                    |   |   |
| Exercised                        |   | (6,930     | )      |                                          | 0.21   |                                                     |   |                    |   |   |
| Forfeited/Canceled               |   | (557,400   | )      |                                          | 0.67   |                                                     |   |                    |   |   |
| Outstanding on December 31, 2009 |   | 2,130,440  |   |                                          | 0.40   |                                                     |   |                    |   |   |
| Granted                          |   | 25,000     |   |                                          | 0.36   |                                                     |   |                    |   |   |
| Exercised                        |   | (306,900   | )      |                                          | 0.15   |                                                     |   |                    |   |   |
| Forfeited/Canceled               |   | (650,150   | )      |                                          | 0.63   |                                                     |   |                    |   |   |
| Outstanding on December 31, 2010 |   | 1,198,390  |   |                                          | $      | 0.30                                                     |   |                    | 4.0    |   |   | $ | 80,141 |   |
| Exercisable on December 31, 2010 |   | 894,460    |   |                                          | $      | 0.28                                                     |   |                    | 3.5    |   |   | $ | 80,109 |   |

|                                               |        |          |        |                                                                         |      |        |        |
|-----------------------------------------------|--------|----------|--------|-------------------------------------------------------------------------|------|--------|--------|
|                                          |   | Shares   |   | Weighted AverageGrant Date FairValue per Share |
| Non-vested stock options January 1, 2010      |   | 871,750  |   |                                                                    | $    | 0.55   |   |
| Non-vested stock options granted              |   | 25,000   |   |                                                                    | 0.32 |   |
| Vested stock options                          |   | (178,203 | )      |                                                                    | 0.51 |   |
| Forfeited stock options                       |   | (414,617 | )      |                                                                    | 0.61 |   |
| Non-vested stock options at December 31, 2010 |   | 303,930  |   |                                                                    | 0.46 |   |

|                                                |        |                                        |        |        |         |        |         |         |        |   |         |        |
|------------------------------------------------|--------|----------------------------------------|--------|--------|---------|--------|---------|---------|--------|---|---------|--------|
|                                           |   | Year Ended December 31, |
|                                           |   | 2010                                   |   | 2009   |    | 2008   |
| Grant date fair value of stock options granted |   | $                                      | 8,100  |   |    | $      | 153,276 |    |   | $ | 226,230 |   |
| Grant date fair value of stock options vested  |   | 90,810                                 |   |   | 116,206 |   |    | 120,350 |   |
| Intrinsic value of stock options exercised     |   | 47,151                                 |   |   | 1,178   |   |    | 611,190 |   |

----

|                                                          |        |                         |         |        |         |        |          |         |        |   |           |        |
|----------------------------------------------------------|--------|-------------------------|---------|--------|---------|--------|----------|---------|--------|---|-----------|--------|
|                                                     |   | Year Ended December 31, |
|                                                     |   | 2010                    |    | 2009   |    | 2008   |
| Federal income tax expense (benefit) at statutory rate   |   | $                       | 303,010 |   |    | $      | (110,110 | )       |   | $ | 910,043   |   |
| State income taxes, net of federal benefit               |   | 5,529                   |    |   | 13,582  |   |     | 5,559   |   |
| Share-based compensation                                 |   | 15,306                  |    |   | 44,060  |   |     | 38,296  |   |
| Effect of foreign operations, net of foreign tax credits |   | (9,957                  | )       |   | (10,023 | )      |     | (17,130 | )      |
| Change in valuation allowance                            |   | 91,537                  |    |   | 135,733 |   |     | 65,504  |   |
| Other, net                                               |   | (71,964                 | )       |   | (62,242 | )      |     | 58,565  |   |
| Income tax expense                                       |   | $                       | 333,461 |   |    | $      | 11,000   |    |   | $ | 1,060,837 |   |

|                                        |        |              |          |        |          |        |          |        |
|----------------------------------------|--------|--------------|----------|--------|----------|--------|----------|--------|
|                                   |   | December 31, |
|                                   |   | 2010         |     | 2009   |
| Deferred tax assets related to:        |   |         |     |   |
| Inventories                            |   | $            | 338,283  |   |     | $      | 391,524  |   |
| Accounts receivable and other assets   |   | 10,625       |     |   | 9,811    |   |
| Accrued liabilities                    |   | 72,267       |     |   | 75,685   |   |
| Tax loss and tax credit carryforwards  |   | 451,744      |     |   | 318,479  |   |
| Other                                  |   | 10,704       |     |   | 7,490    |   |
|                                   |   | 883,623      |     |   | 802,989  |   |
| Valuation allowance                    |   | (410,258     | )        |   | (318,721 | )      |
| Net deferred tax assets                |   | 473,365      |     |   | 484,268  |   |
| Deferred tax liabilities related to:   |   |         |     |   |     |   |
| Property and equipment                 |   | (520,004     | )        |   | (485,857 | )      |
| Intangible assets                      |   | (551,855     | )        |   | (492,392 | )      |
| Deferred tax liabilities               |   | (1,071,859   | )        |   | (978,249 | )      |
| Net deferred tax liabilities           |   | $            | (598,494 | )      |     | $      | (493,981 | )      |
|                                   |   |         |     |   |
| Net current deferred tax assets        |   | $            | 396,415  |   |     | $      | 449,254  |   |
| Net long-term deferred tax liabilities |   | (994,909     | )        |   | (943,235 | )      |
|                                   |   | $            | (598,494 | )      |     | $      | (493,981 | )      |

----

|                    |        |                         |         |        |         |        |          |         |        |   |           |        |
|--------------------|--------|-------------------------|---------|--------|---------|--------|----------|---------|--------|---|-----------|--------|
|               |   | Year Ended December 31, |
|               |   | 2010                    |    | 2009   |    | 2008   |
| Current            |   |                    |    |   |    |   |
| Federal            |   | $                       | 228,948 |   |    | $      | (211,772 | )       |   | $ | 943,498   |   |
| Foreign            |   | —                 |    |   | — |   |     | — |   |
| Deferred           |   |                    |    |   |    |   |
| Federal            |   | 104,513                 |    |   | 222,772 |   |     | 117,339 |   |
| Foreign            |   | —                 |    |   | — |   |     | — |   |
| Income tax expense |   | $                       | 333,461 |   |    | $      | 11,000   |    |   | $ | 1,060,837 |   |

|                         |        |         |        |
|-------------------------|--------|---------|--------|
| Year ended December 31, |   |
| 2011                    | $      | 98,132  |   |
| 2012                    | 75,224 |    |
| 2013                    | 6,500  |    |
|                    | $      | 179,856 |   |

----

|                               |        |                           |        |                       |         |              |        |        |        |   |        |        |
|-------------------------------|--------|---------------------------|--------|-----------------------|---------|--------------|--------|--------|--------|---|--------|--------|
|                          |   | Nutritional Products |   | Medical Products |    | Consolidated |
| Year ended December 31, 2010  |   |                      |   |                  |    |         |
| Net sales                     |   | $                         | 21,613 |                  |    | $            | 6,544  |   |   | $ | 28,157 |   |
| Depreciation and amortization |   | 458                       |   |                  | 81      |         |   | 539    |   |
| Operating profit              |   | 675                       |   |                  | 369     |         |   | 1,044  |   |
| Capital expenditures          |   | 163                       |   |                  | — |         |   | 163    |   |
| Total assets                  |   | 15,503                    |   |                  | 2,841   |         |   | 18,344 |   |
| Year ended December 31, 2009  |   |                      |   |                  |    |         |   |   |   |
| Net sales                     |   | $                         | 18,779 |                  |    | $            | 6,146  |   |   | $ | 24,925 |   |
| Depreciation and amortization |   | 386                       |   |                  | 70      |         |   | 456    |   |
| Operating profit (loss)       |   | (504                      | )      |                  | 344     |         |   | (160   | )      |
| Capital expenditures          |   | 1,116                     |   |                  | 19      |         |   | 1,135  |   |
| Total assets                  |   | 15,787                    |   |                  | 2,826   |         |   | 18,613 |   |
| Year ended December 31, 2008  |   |                      |   |                  |    |         |   |   |   |
| Net sales                     |   | $                         | 24,061 |                  |    | $            | 6,348  |   |   | $ | 30,409 |   |
| Depreciation and amortization |   | 277                       |   |                  | 97      |         |   | 374    |   |
| Operating profit              |   | 2,523                     |   |                  | 329     |         |   | 2,852  |   |
| Capital expenditures          |   | 560                       |   |                  | 31      |         |   | 591    |   |
| Total assets                  |   | 17,247                    |   |                  | 2,519   |         |   | 19,766 |   |

----

|                              |        |           |        |                   |         |        |       |        |
|------------------------------|--------|-----------|--------|-------------------|---------|--------|-------|--------|
|                         |   | Net Sales |   | Long-lived Assets |
| Year ended December 31, 2010 |   |      |   |              |
| Domestic                     |   | $         | 10,792 |              |    | $      | 6,543 |   |
| Russia/Eastern Europe        |   | 15,375    |   |              | — |   |
| Canada                       |   | 1,066     |   |              | 542     |   |
| All others                   |   | 924       |   |              | — |   |
| Totals                       |   | $         | 28,157 |              |    | $      | 7,085 |   |
| Year ended December 31, 2009 |   |      |   |              |    |   |
| Domestic                     |   | $         | 11,015 |              |    | $      | 6,831 |   |
| Russia/Eastern Europe        |   | 12,477    |   |              | — |   |
| Canada                       |   | 1,071     |   |              | 552     |   |
| All others                   |   | 362       |   |              | — |   |
| Totals                       |   | $         | 24,925 |              |    | $      | 7,383 |   |
| Year ended December 31, 2008 |   |      |   |              |    |   |
| Domestic                     |   | $         | 10,818 |              |    | $      | 6,365 |   |
| Russia/Eastern Europe        |   | 17,799    |   |              | — |   |
| Canada                       |   | 1,115     |   |              | 476     |   |
| All others                   |   | 677       |   |              | — |   |
| Totals                       |   | $         | 30,409 |              |    | $      | 6,841 |   |

----

|                                   |        |                               |           |        |           |                |        |        |        |       |        |
|-----------------------------------|--------|-------------------------------|-----------|--------|-----------|----------------|--------|--------|--------|-------|--------|
|                              |   | Net Earnings (Loss) |      | Shares |      | Per Share |
| Year ended December 31, 2010      |   |                          |      |   |      |           |
| Basic earnings per common share   |   | $                             | 557,746   |   |      | 21,998,659     |   |   | $      | 0.03  |   |
| Effect of dilutive stock options  |   | —                       |      |   | 437,038   |           |   |   |   |
| Diluted earnings per common share |   | $                             | 557,746   |   |      | 22,435,697     |   |   | $      | 0.02  |   |
|                              |   |                          |      |   |      |           |
| Year ended December 31, 2009      |   |                          |      |   |      |           |   |   |   |
| Basic loss per common share       |   | $                             | (334,853  | )      |      | 21,920,779     |   |   | $      | (0.02 | )      |
| Effect of dilutive stock options  |   | —                       |      |   | —   |           |   |   |   |
| Diluted loss per common share     |   | $                             | (334,853  | )      |      | 21,920,779     |   |   | $      | (0.02 | )      |
|                              |   |                          |      |   |      |           |
| Year ended December 31, 2008      |   |                          |      |   |      |           |   |   |   |
| Basic earnings per common share   |   | $                             | 1,615,760 |   |      | 21,464,832     |   |   | $      | 0.08  |   |
| Effect of dilutive stock options  |   | —                       |      |   | 1,374,026 |           |   |   |   |
| Diluted earnings per common share |   | $                             | 1,615,760 |   |      | 22,838,858     |   |   | $      | 0.07  |   |

----

|                            |        |                                                   |        |         |        |              |        |             |        |        |        |        |        |   |       |        |
|----------------------------|--------|---------------------------------------------------|--------|---------|--------|--------------|--------|-------------|--------|--------|--------|--------|--------|---|-------|--------|
|                       |   | Quarter Ended                                     |
|                       |   | March 31                                          |   | June 30 |   | September 30 |   | December 31 |
|                       |   | (Unaudited - In thousands, except per share data) |
| 2010                       |   |                                              |   |    |   |         |   |        |
| Net sales                  |   | $                                                 | 6,982  |    |   | $            | 7,838  |        |   | $      | 6,126  |   |   | $ | 7,211 |   |
| Gross profit               |   | 3,389                                             |   |    | 3,656  |         |   | 3,290       |   |   | 3,351  |   |
| Net earnings               |   | 211                                               |   |    | 172    |         |   | 134         |   |   | 41     |   |
| Earnings per share:        |   |                                              |   |    |   |         |   |        |
| Basic                      |   | 0.01                                              |   |    | 0.01   |         |   | 0.01        |   |   | 0.00   |   |
| Diluted                    |   | 0.01                                              |   |    | 0.01   |         |   | 0.01        |   |   | 0.00   |   |
|                       |   |                                              |   |    |   |         |   |        |
| 2009                       |   |                                              |   |    |   |         |   |        |   |   |   |   |
| Net sales                  |   | $                                                 | 6,016  |    |   | $            | 6,759  |        |   | $      | 6,487  |   |   | $ | 5,663 |   |
| Gross profit               |   | 3,139                                             |   |    | 3,521  |         |   | 3,215       |   |   | 2,927  |   |
| Net earnings (loss)        |   | (171                                              | )      |    | 277    |         |   | (152        | )      |   | (289   | )      |
| Earnings (loss) per share: |   |                                              |   |    |   |         |   |        |
| Basic                      |   | (0.01                                             | )      |    | 0.01   |         |   | (0.01       | )      |   | (0.01  | )      |
| Diluted                    |   | (0.01                                             | )      |    | 0.01   |         |   | (0.01       | )      |   | (0.01  | )      |

----

|                     |        |                                                                                                                                                       |
|---------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exhibit Number |   | Description                                                                                                                                           |
|                |   |                                                                                                                                                  |
| 21.1                |   | List of company subsidiaries                                                                                                                          |
|                |   |                                                                                                                                                  |
| 23.1                |   | Consent of Lane Gorman Trubitt, PLLC, independent registered public accountants to incorporation of report by reference                               |
|                |   |                                                                                                                                                  |
| 31.1                |   | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                |
|                |   |                                                                                                                                                  |
| 31.2                |   | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                |
|                |   |                                                                                                                                                  |
| 32.1                |   | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|                |   |                                                                                                                                                  |
| 32.2                |   | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |